SPOTLIGHT -
May 23rd 2023
Diagnose, monitor, comanage—optometrists support patients throughout all stages of the disease.
April 24th 2023
The GA Won’t Wait campaign is designed to help older adults and their families understand and recognize the symptoms of this progressive and irreversible disease.
April 22nd 2023
Catch up on what happened in optometry during the week of April 17-April 21.
April 17th 2023
One way to advance the current understanding of GA is to study how disease progression varies among related individuals.
April 15th 2023
A look back on what happened in optometry during the week of April 10-April 14.
Q&A: How is the landscape of geographic atrophy changing?
Pegcetacoplan’s recent FDA approval creates an option for patients with dry AMD.
This week in optometry: April 3-April 7
A look back on what happened in optometry during the week of April 3-April 7.
OCT biomarkers associated with advanced age-related macular degeneration
Imaging can elucidate visual prognosis and disease progression risk.
Do diabetes, diabetic retinal disease contribute to macular degeneration?
These disorders account for most of the vision loss in working-age and elderly Americans.
Pegcetacoplan approved by FDA for the treatment of geographic atrophy
Following the submission of the 24-month phase 3 data in November 2022, Apellis received FDA approval for intravitreal pegcetacoplan (SYFOVRE) to treat geographic atrophy secondary to AMD.
Geographic atrophy: What to know and why
Look out for at-risk patients and prepare to establish treatment protocols.
Apellis aims to submit 24-month Phase 3 data to FDA for pegcetacoplan NDA
The submission of 24-month efficacy data from DERBY and OAKS is classified as a Major Amendment to the New Drug Application, which delays the PDUFA target action date until February 2023.
Apellis releases 24-month results of phase 3 studies for GA treatment
Latest data from phase 3 studies finds increased effects over time with intravitreal pegcetacoplan for geographic atrophy secondary to age-related macular degeneration.
Apellis receives FDA acceptance, priority review of NDA for GA treatment
If approved, pegcetacoplan—an investigational, targeted C3 therapy—will be the first-ever treatment for GA.
Imaging technology helps in scanning for retinal diseases
Advancements enable better diagnosis, treatment of patients.
Apellis submits NDA to FDA for geographic atrophy treatment
A decision by the FDA is expected in August 2022.
What’s hot (and not) in retinal news
A look at the latest developments in retinal disease, including clinical trials and advanced therapies.
Apellis releases 18-month results from phase 3 studies of pegcetacoplan for GA
New detailed, longer-term findings were presented at the 2022 ARVO meeting.